Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: J Thorac Oncol. 2011 Sep;6(9):1521–1529. doi: 10.1097/JTO.0b013e3182289479

Figure 4.

Figure 4

Activation of NF-κB targets in tumors with aberrant expression of KEAP1 E3-ligase complex components and/or IKBKB. (A–D) Box and whisker plots demonstrating four examples of NF-κB target genes (BCL2L11, CXCL13, MMP9, TRAF1) that are significantly upregulated in tumors with underexpression of KEAP1, RBX1, and/or CUL3 or overexpression of IKBKB, relative to matched non-malignant lung tissues (Wilcoxon sign rank test, p ≤ 0.001). Copy number status of the NF-κB target gene loci was determine in these tumors to ensure that overexpression was not due to dosage changes of the target genes.